Objective: To evaluate longitudinal growth, pubertal development and ®nal height in patients with congenital hypothyroidism (CH) detected by a neonatal screening programme, and to identify factors potentially affecting growth outcome. Patients: Fifty-®ve patients (41 females) detected by neonatal screening and followed longitudinally from the time of diagnosis and treatment (25^5 days) up to the age of 17^0X5 years were evaluated retrospectively. Results: Pubertal development began and progressed normally in both males and females. In boys, a testicular volume of 4 ml was reached at 11X3^1X0 years. In girls breast enlargement (B2) occurred at a mean age of 10X3^1X2 years and the mean age of menarche was 12X5^1X2 years. The onset and the progression of puberty were independent of the aetiology, the severity of CH and the timing of the beginning of treatment. Girls treated with an initial amount of L-thyroxine (L-T 4 ) greater than 8 mg/kg per day showed an earlier onset of puberty (B2 9X4^0X9 years; menarche 11X5^0X8 years) compared with girls treated with a lower initial dose of L-T 4 (B2 10X5^1X2 years; menarche 12X6^1X2 years; P , 0X02). However, both groups attained a similar ®nal height (20X1^1X0 SDS and 0X4^1X0 SDS, respectively), which in both cases was above the target height P 0X03X All the patients in the study attained a mean ®nal height (0X1^1X1 SDS) within the normal range for the reference population and above the target height 20X9^0X9 SDS, P , 0X0001X No signi®cant relationship was found between ®nal height and severity of CH at diagnosis, initial L-T 4 dosage or aetiology of the defect. Patients with ectopic gland, thyroid aplasia or in situ gland attained a similar mean ®nal height (0X1^1X1 SDS, 0X5^1X0 SDS and 20X5^1X0 SDS, respectively), which was in all cases greater than target height 21X0^0X9Y 20X6^0X8Y 20X9^0X8 respectively; P , 0X05X Conclusions: Our results suggest that conventional management of children with CH detected by neonatal screening leads to normal sexual development and normal adult height, and that the major factor determining height in these children is familial genetic growth potential.
Introduction
Thyroid hormones are essential for normal growth and brain development. Although the introduction of systematic neonatal screening for congenital hypothyroidism (CH) has prevented brain damage, subtle neurological dysfunctions or subnormal intelligence quotients, despite early diagnosis and treatment, have been reported in some cases (1±4). It is generally accepted that the degree of hypothyroidism at diagnosis, the timing of the onset of treatment and the doses of replacement L-thyroxine (L-T 4 ) are the major determinants of intellectual outcome (5±8).
Whether these factors may affect also linear growth in children with CH, detected by screening and treated from early infancy, remains controversial. Several studies have in fact reported a normal linear growth in infancy and childhood (9±11), whereas others found a slightly deviant growth in the ®rst years of life in children with severe CH at diagnosis (12±14). Recent data on ®nal height in patients with CH, detected by neonatal screening, suggest that the amount of replacement L-T 4 received in the ®rst 6 months of life may strongly in¯uence the attainment of normal adult height (15) .
The aim of the present study was to evaluate retrospectively the longitudinal growth, pubertal development and ®nal height in patients with CH detected by neonatal screening and to identify factors potentially affecting growth outcome.
Patients and methods
Of the 60 children referred to our department between 1981 and 1984 by the regional screening programme for congenital hypothyroidism, ®ve were lost to followup. The remaining 55 patients (41 females) were followed longitudinally from the time of diagnosis until they reached their ®nal height. The diagnosis was con®rmed by serum thyroid function tests. Therapy with L-T 4 was begun immediately after the ®rst evaluation, at a mean chronological age of 25^5 days (range 11±31 days), at an initial dose of 25 mg, given orally once a day, which represented a mean of 7X0^1X8 mgakg body weight. Initial L-T 4 dosage was modi®ed during follow-up according to clinical and biochemical observations in an attempt to keep serum T 4 and free T 4 concentrations in the upper normal range and serum thyroid-stimulating hormone (TSH) in the normal range. Children were evaluated at the ages of 3, 6, 9 and 12 months of life, then every 3 or 6 months until the age of 3 years, and annually thereafter.
The aetiological diagnosis of CH was performed by 99m Tc-pertechnetate or iodine-123 thyroid scans, either at the time of diagnosis or at the age of 3 years after the withdrawal of L-T 4 therapy for 6 weeks. Twenty-®ve children were classi®ed as having ectopic glands, 10 had thyroid aplasia and 11 showed an in situ gland.
Skeletal maturity was assessed annually using the atlas of Greulich & Pyle (16) and predicted adult height was estimated by the method of Bayley & Pinneau (17) .
Supine length until 2 years of age and standing height thereafter were measured using a Harpenden stadiometer and expressed as standard deviation score (SDS) for chronological age according to Tanner et al. (18) . British growth standards were chosen because they proved to be similar to our regional percentiles (19) . Final height, evaluated at a mean age of 16X50 X5 years in females and 17X5^0X5 years in males, was de®ned as a growth velocity of less than 1 cm in the preceding year. Parental height was measured at referral and SDS of the genetic target height (sexcorrected mid-parental height) was calculated according to Tanner et al. (18) . Final height was also expressed as the percentage of target height achieved by the patients.
The increase in weight was expressed as body mass index (BMI), calculated by dividing weight in kilograms by the square of the height (20) , and was compared with reference percentiles according to Must et al. (21) .
The onset of puberty was de®ned by the beginning of breast development (B2) in girls and the enlargement of testicular volume to 4 ml (G2) in boys. Pubertal growth was evaluated using the total pubertal height gain from the onset of puberty to ®nal height (22) .
Statistical analysis
Statistical analysis was performed using the Student's t-test or Mann±Whitney rank sum test as appropriate, and linear regression analysis. A P value ,0.05 was considered statistically signi®cant. Results are reported as mean^S.D.
Results
Main clinical data on pubertal development and ®nal height for both boys and girls are reported in Table 1 . The onset of puberty occurred at normal ages in both males and females; menarche, in females, occurred at a mean age of 12X5^1X2 years, which was similar to the age observed in a regional control group of 50 healthy young girls (12X5^1X0 years). Mean total pubertal growth was normal in boys 28X2^5X5 cm and slightly decreased in girls 21X4^5X5 cm compared with mean values reported by Tanner (28 cm in boys and 25 cm in girls) (23) . Nevertheless, both males and females attained a mean adult height within the normal range for the reference population and above the target height P 0X02 (Fig. 1 ). Final height was positively correlated with target height r 0X80Y P , 0X0001Y with predicted adult height at 7 years of age r 0X90Y P , 0X0001 and with height both at onset of puberty r 0X72Y P , 0X0001 and at menarche r 0X91Y P , 0X0001X Figure 2 shows the longitudinal increase in length/ height and BMI in boys and girls. The linear growth ( Fig. 2A) progressed similarly in males and females through infancy and childhood. In both sexes BMI ( Fig. 2B ) was above the 95th percentile until 6 years of age (greater than the reference population for sex and age) and ranged between the 50th and the 85th percentile in the subsequent years.
Bone age maturation (Fig. 2C ) was delayed in the ®rst years of follow-up compared with chronological age; however, by the age of 5 years the bone age/ chronological age ratio was 1 for both boys and girls, and the increase in skeletal maturation paralleled the increase in chronological age. No signi®cant differences were observed in longitudinal growth, pubertal development and ®nal height between patients with different aetiologies of the defect: the longitudinal increases in length/height (Fig. 3A) and in BMI (Fig. 3B) were similar in patients with ectopic gland, thyroid aplasia and in situ gland. All patients reached adult heights that were normal according to the predicted adult height at the age of 7 years and above the genetic target P , 0X05 (Fig. 4) .
The onset of puberty, the age of menarche and the ®nal height were not in¯uenced by the severity of hypothyroidism at diagnosis. In females with severe hypothyroidism at diagnosis (serum T 4 ,3 mg/dl) the onset of puberty (10X4^1X3 years) and menarche (12X5^1X2 years) occurred at the same ages (10X1^1X2 and 12X4^1X2 years respectively) as in girls with moderate hypothyroidism (serum T 4 .3 mg/dl). In males the onset of puberty occurred at a similar age 11X8^1X3 years and 11X0^0X8 years in patients with severe or moderate hypothyroidism respectively. Mean ®nal height in all the patients (males and females) with severe CH did not differ from that of those with the moderate form (Fig. 5 ) and in both groups it was greater than target height P , 0X0001X
In 11 girls treated with an initial L-T 4 dose greater than 8 mg/kg per day, puberty occurred earlier than in 30 girls treated with an initial lower amount of L-T 4 (,8 mg/kg per day); nevertheless, ®nal height was similar in both groups ( Table 2 ). As depicted in Fig. 6 all patients, boys and girls, attained a normal adult height signi®cantly greater than the genetic potential P , 0X05Y independently of the initial amount of L-T 4 .
In addition, no signi®cant relationships were found between the L-T 4 dose during the ®rst 3±6 or 12 months of treatment, the compliance with the treatment (evaluated by the mean serum TSH values during the ®rst 2 years of life or during the period 2±10 years of age) and pubertal development or the ®nal height (data not shown).
No signi®cant differences were observed in sexual maturation and ®nal height between patients treated before and after the ®rst 3 weeks of life (data not shown). In order to evaluate better the impact of chronological age at the beginning of treatment on pubertal development and ®nal height, data from the patients in the study were compared with those from 46 patients with CH diagnosed, in our department, before the introduction of neonatal screening. Despite the late diagnosis and treatment (8X0^7X0 months) and the low amount of initial L-T 4 administered (4X9^2X5 mgakg per day), patients showed a normal sexual maturation and reached a mean adult height (20X4^0X8 SDS) above their target height 21X0^0X9 SDS; P 0X001X However, height at diagnosis and ®nal height were signi®cantly shorter compared with those of patients detected earlier by neonatal screening P , 0X02Y despite a similar target height (Fig. 7) .
Discussion
There is no doubt that linear growth, pubertal development and ®nal height are normal in children with CH treated from the ®rst weeks of life. Several data have been reported on linear growth during infancy and childhood. However, whereas some authors report a normal linear growth (9±11), others provide evidence of a signi®cant delay of increase in length during the ®rst year of life in children with athyreosis (24) and in patients with more severe hypothyroidism at diagnosis (12±14). The only data available on adult height, in a small group of patients with CH (15), indicate that a large daily dose of L-T 4 is necessary in the ®rst 6 months of treatment if the child is to attain a normal adult height. Therefore the question as to whether linear growth and ®nal height might be affected by several factors, as is the case for intellectual outcome, seems to be controversial.
Our results indicate that puberty began within a normal age span and progressed normally in boys and girls, independently of the aetiology of CH, the severity of CH, and the timing of the beginning of treatment. In fact patients diagnosed after the ®rst months of life, before the introduction of neonatal screening, also showed a normal pattern of pubertal development. Although few girls initially treated with a larger amount of L-T 4 showed an earlier onset of puberty, mean ®nal height did not differ from that of girls treated with a lower starting dose of L-T 4 . All patients in the study attained a mean ®nal height within the normal range for the reference population and above the target height. We did not ®nd any relationship between ®nal height and severity of CH at diagnosis, L-T 4 dosage at beginning of treatment, or aetiology of the defect. Patients with a more severe hypothyroidism at diagnosis and those with thyroid aplasia reached a mean ®nal height that was not signi®cantly different from that of the other group and in all cases it was greater than their genetic target. In patients treated within the ®rst month of life, no signi®cant differences were observed either in height at the beginning of treatment or in ®nal height comparing patients treated before or after the ®rst 3 weeks of life. However, the delay in treatment in patients diagnosed before the introduction of systematic neonatal screening resulted in a severely short stature at the beginning of treatment and a mean adult height signi®cantly shorter than that achieved by patients detected by neonatal screening.
Patients with CH were heavier than the reference population, not only in the ®rst years of life (12) , but also during childhood and adolescence. However, the increase in weight was not correlated with any one of the factors just considered for the linear growth. The overweight status observed in several patients with CH deserves further attention as, far from being related to a condition of under-treatment, it might be the result of an incorrect parent±child affective relationship ®nally results in an overfeeding of child and adolescent (4).
Our results, in agreement with those of Dickerman & De Vries (15) , indicate that patients with CH have a normal sexual maturation and attain a normal adult height; however, we did not observe any relationship between ®nal height and L-T 4 dosage, either at the beginning or during the ®rst year of treatment. Moreover, we have recently demonstrated that greater initial doses of L-T 4 do not improve linear growth in the ®rst 4 years of age, the growth pattern for height and weight being similar in the low-dose treated and the high-dose treated patients (25) .
In conclusion, our results suggest that conventional management of children with CH detected by neonatal screening leads to normal sexual development and normal adult height, and that the major factor determining height in these children is familial genetic growth potential.
